PRAME Immunostain, Technical Component Only
Use
PRAME (Preferentially expressed Antigen in Melanoma) expression in melanocytic neoplasms is strongly associated with melanoma and may be useful in differentiating benign nevi from malignant melanocytic lesions. This test aids in the differentiation between melanoma and benign nevi through immunohistochemical staining, providing support in challenging diagnostic cases.
Special Instructions
Not provided.
Limitations
The test does not include pathologist interpretation, only technical performance of the stain. Interpretation of this test should be performed in context with the patient's clinical history and other diagnostic tests by a qualified pathologist. The age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Environmental factors can also affect the charge of glass slides and subsequently alter slide staining.
FDA ApprovedNew York Approved
Methodology
Immunoassay (IHC)
Biomarkers
PRAME
Protein
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Immunostain Technical Only Envelope
Causes for Rejection
Wet/frozen tissue, cytology smears, nonformalin fixed tissue, nonparaffin embedded tissue, noncharged slides, ProbeOn slides, Snowcoat slides